Fulgent Genetics Inc (FLGT) financials
Fulgent Genetics revenue and earnings by year
Fulgent Genetics's revenue was $323 million in the fiscal year to December 31, 2025, up 13.8% from the year before. Net income was -$60.5 million, -18.8% of revenue. Since the fiscal year to December 31, 2016, revenue has grown 37.6% a year on average.
Fiscal years, each labelled by the calendar year it ended in.
Income statement, the last 10 fiscal years
| Fiscal year to | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 | Dec 2019 | Dec 2018 | Dec 2017 | Dec 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 323 | 283 | 289 | 619 | 993 | 422 | 33 | 21 | 19 | 18 |
| Revenue growth | 13.8% | -2.0% | -53.3% | -37.6% | 135.4% | 1196.5% | 52.3% | 14.0% | 2.5% | — |
| Gross profit | 131 | 107 | 104 | 367 | 777 | 332 | 18 | 11 | 10 | 12 |
| Gross margin | 40.6% | 37.8% | 36.1% | 59.3% | 78.3% | 78.7% | 56.6% | 49.9% | 54.3% | 63.2% |
| Operating income | -91 | -74 | -196 | 179 | 676 | 290 | -0 | -5 | -3 | 1 |
| Operating margin | -28.2% | -26.1% | -67.6% | 28.8% | 68.1% | 68.8% | -1.3% | -23.7% | -18.6% | 5.0% |
| Net income | -61 | -43 | -168 | 143 | 507 | 214 | -0 | -6 | -3 | -5 |
| Net margin | -18.8% | -15.1% | -58.0% | 23.2% | 51.1% | 50.8% | -1.3% | -26.3% | -13.4% | -29.3% |
| Diluted EPS | -$1.96 | -$1.41 | -$5.64 | $4.61 | $16.38 | $8.87 | -$0.01 | -$0.31 | -$0.14 | — |
| Free cash flow | -124 | -19 | 6 | 235 | 515 | 106 | 4 | -4 | -4 | 1 |
Diluted EPS is stated in today's shares (adjusted for every split since). Quarterly statements and the income statement as a flow chart are in the app: open FLGT in Markets.
How Fulgent Genetics makes money
Revenue by segment in the quarter to June 30, 2026, as the company reports it.
| Segment | Revenue | Share |
|---|---|---|
| Laboratory Services | $85.4M | 100.0% |
| Therapeutic Development | $30.0K | 0.0% |
See also: FLGT valuation and P/E history · FLGT returns
No forecast, no recommendation. This page describes Fulgent Genetics Inc from published data; it is not advice to buy, sell or hold any security.
Figures as of the close on Oct 30, 2026 unless a row says otherwise. Prices are split adjusted; returns include dividends reinvested. Data may be delayed. See the disclaimer and how TrendArc works.